Naarden · Pre-Seed–Late Stage · 27 people tracked
Also known as BIOGENERATION III SERVICES B.V.
Investment thesis
Seed-focused, investing pre-seed through growth, they leverage Forbion integration for privileged later-stage networks and serve as registered manager bridging academic spin-outs via a DCVA/RegMed pre-seed program.
Source: firm website, verified Jul 31, 2026.
Team · 27 people
from the firm's website & curated & public directories
Founder mafia
2 people who came through BioGeneration Ventures went on to found or lead other companies.
What they invest in
from 23 of 28 portfolio companiesBiotech ×21Healthtech ×13Medical Devices ×10Deep Tech ×7Digital Health ×3AI & Machine Learning ×1Impact & Social Good ×1
HQs:Netherlands×4United States×3Switzerland×1Germany×1
Investments · 28 tracked
founders shown can be your intro pathBy year:2024 · 12023 · 12021 · 13 dated
Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach.
BiotechDeep TechHealthtech
Tjeerd Barf(Co-founder & CEO)inArwin Ridder(Co-founder & COO)inAd IJzerman(Co-founder & SAB Chair)inJason(Chief Scientific Officer)in
Co-investorsThuja CapitalSeroba Life SciencesBGV
Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases.
AI & Machine LearningBiotech
Co-investorsEQT Life SciencesBOMCurie CapitalKurma PartnersV-Bio Ventures
i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.
BiotechDeep TechHealthtech
Co-investorsTorrey Pines InvestmentOrbiMed
RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.
BiotechDigital HealthMedical DevicesBasel, CH
Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)Katherine High(CEO)
Co-investorsARCH Venture PartnersNovartis Venture FundF-Prime CapitalGV (Google Ventures)
Seattle, US
Meininger David(Executive Officer, Director, Promoter)
BoardRoger Ulrich(Director)Daniel O'Connell(Director)
Board seatEdward van Wezel· per SEC Form D · $17.3M raise · filed Apr 2021
Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism.
BiotechMedical Devices
Co-investorsBioMedPartnersForbionJeito CapitalSeroba Life Sciences
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a protein it identified as a cancer therapy resistance mechanism, aiming to restore anti-tumor immune activity and improve responses to checkpoint inhibitors.
BiotechHealthtech
Co-investorsBayern KapitalCanaan PartnersJeito CapitalNovartis Venture FundBioqube Ventures
Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa.
BiotechHealthtechMedical DevicesOss, NL
Co-investorsBOMCurie CapitalNovartis Venture FundPureos BioventuresForbion
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.
BiotechDigital HealthHealthtechMedical DevicesMunich, DE
Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in
Co-investorsHadean VenturesSeroba Life SciencesCambridge Innovation Capital
Co-investorsCapricorn Venture PartnersFund+PMVQuest for GrowthV-Bio Ventures
Cristal Therapeutics develops a proprietary copper-free click chemistry platform, CliCr®, used to create bioconjugate products with higher stability and faster reaction rates.
BiotechDeep Tech
Co-investorsBOMDroia VenturesThuja Capital
Co-investorsEpidarex Capital
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)Cristina Oliva(Chief Medical Officer)Nick Robbins-Cherry(Chief Financial Officer)Elizabeth Hardaker(Chief Translational Science Officer)
Co-investors3B Future Health FundAlbionVCEpidarex CapitalGlobal BioAccess FundNovartis Venture FundUCL Technology Fund
The National Kidney Foundation is a nonprofit organization focused on kidney disease, providing patient education, emotional support, and resources for patients, families, living donors, and transplant recipients.
HealthtechImpact & Social Good
Co-investorsYsios CapitalEpidarex CapitalRoche Venture FundScottish National Investment BankSofinnova Partners
Kivu Bioscience is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, using site-specific conjugation technology to create more stable and homogeneous cancer therapies with reduced off-tumor toxicity.
BiotechDeep TechHealthtech
Mohit Trikha(CEO)
Co-investorsBOMHealthCapM VenturesRed Tree VentureNovo Holdings
Mellon Medical develops suturing tools for medical specialists, aiming to improve patient outcomes and reduce healthcare costs.
HealthtechMedical Devices
Co-investorsBOMThuja Capital
Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.
BiotechMedical Devices
Adele Rowley(Chief Scientific Officer)
Co-investorsEpidarex CapitalRoche Venture FundSofinnova PartnersScottish National Investment Bank
River Biomedics develops human cardiac in vitro models used for drug target and compound validation, building a pipeline of cardiac therapies.
BiotechHealthtechMedical Devices
Co-investorsKIKK Capital
Scenic Biotech develops disease-modifying therapies for patients with neurological and metabolic genetic disorders using its Cell-Seq discovery platform to identify modifier genes.
BiotechDeep TechHealthtech
Co-investorsBioMedPartnersEIR VenturesOxford Science EnterprisesInkef
STANT b.v. develops small-molecule STING pathway antagonists with a differentiated mechanism of action, targeting autoimmune, inflammatory, cardiovascular, metabolic and neurodegenerative diseases such as systemic lupus erythematosus, ALS, Parkinson's and chronic kidney disease.
BiotechDeep TechHealthtechOss, NL
Søren R. PaludanSonia Assil
Synaffix develops antibody-drug conjugate (ADC) technology, providing linker-payload platforms that attach small-molecule, peptide, and protein-based payloads to antibodies for use in targeted cancer therapies.
BiotechDeep TechHealthtech
Co-investorsBOMM Ventures
TargED Biopharmaceuticals is a Netherlands-based biotechnology company developing first-in-class biological drugs that use small antibodies (VHH) to deliver enzymes to sites of thrombosis for targeted thrombolysis.
BiotechMedical Devices
Co-investorsAndera PartnersCurie CapitalFund+Hadean VenturesRotripInkef+1 more
Tigatx develops engineered IgA antibodies designed to engage neutrophils as a cancer treatment approach.
Biotech
Co-investorsCivilization Ventures Management, Llc
VarmX is developing VMX-C001, a universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).
BiotechMedical Devices
Co-investorsSound BioventuresUNIIQYsios CapitalBGVEICEQT Life Sciences+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
Mironid · eu-startups.com · Aug 7, 2026
Kidney · eu-startups.com · Aug 7, 2026
Avidicure · avidicure.com · Jun 27, 2025
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Biogeneration Capital Fund V Cooperatief U.A.LPs: California Public Employees' Retirement System | 2023 | — | — | 1.20x | 0.00x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does BioGeneration Ventures invest at?
- BioGeneration Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does BioGeneration Ventures focus on?
- BioGeneration Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is BioGeneration Ventures located?
- BioGeneration Ventures is headquartered in Naarden, NL.
- Does BioGeneration Ventures lead rounds?
- Yes, BioGeneration Ventures leads investment rounds.
Media · Podcasts & interviews
featuring the team#153 Edward van Wezel, BioGeneration Ventures
The European VC · Edward van Wezel
EUVC #45 Daniela Couto, Biogeneration Ventures
EUVC · Daniela Couto
Images
Co-investors · 36
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Inkef is an early-stage, hands-on investor that helps build companies with a long-term strategic vision, aiming for sustainable returns.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.
Bayern Kapital is a venture capital investor backing innovative Bavarian start-ups and scale-ups, providing funding from pre-seed through growth and scale-up stages as an anchor investor across multiple rounds.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Plug and Play is an innovation platform that connects corporations, governments, startups, investors, and universities to drive innovation.
Partech is a global investment firm that backs founders across multiple continents and at every stage through dedicated teams and funds.
Emergence Capital is a venture capital firm that partners with founders building B2B software companies, from early-stage cloud and SaaS pioneers to AI-native innovators.
▶24 more co-investors
Canvas VenturesRidge VenturesStandard CapitalPelion Venture PartnersWildcat Venture PartnersDnx VenturesFusionG2 Venture PartnersWestWave CapitalNational Grid PartnersToyota VenturesJohnson & Johnson Innovation – JJDCInventus Capital PartnersSeventure PartnersMorpheus VenturesTakwin VenturesFirst Rays Venture PartnersWestlake Village BioPartnersAvaana CapitalD.E. ShawSpeciale InvestBenhamou Global VenturesSenseAI VenturesWavemaker Three-Sixty Health
Firms observed investing alongside BioGeneration Ventures, from public investor directories. Shared companies are the overlap with BioGeneration Ventures's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Lightstone Ventures is a life sciences venture firm founded in 2012 that invests in biotech and medtech companies, backing founders translating scientific breakthroughs into therapies and medical technologies.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.